Abstract
Results A total of 33 patients initially treated with Etanercept were switched to Adalimumab after a mean of 25.9 months (range 3–87 months). Reasons for discontinuation of Etanercept were inefficacy (n = 23, 65.8%), uveitis (n = 6, 17.1%), intolerance (n = 3, 8.6%) and patients' request (n = 6, 17.1%). Follow up data on Adalimumab were obtained from 12 patients for a range of 2 to 26 months (mean 10.9 months). The maximum response rate of the PedACR30/50/70 on Etanercept was 82.4%/73.5%/ 67.6%. The last documented response rate on Etanercept showed a decrease to 47.1%/35.3%/29.4% (PedACR30/ 50/70). After switching to Adalimumab a maximum PedACR30/50/70 of 75%/66.7%/50% compared to start of Etanercept and 33.3/33.3/25 compared to start of Adalimumab was reached. Treatment on both drugs was safe with no report of serious AE. Conclusion Although a number of patients have reached a good PedACR response rate on Etanercept, treatment was unsatisfied and therefore it was switched to Adalimumab. According to the PedACR only minor improvement was observed after switching to Adalimumab. from 15th Paediatric Rheumatology European Society (PreS) Congress London, UK. 14–17 September 2008
Highlights
Etanercept has been the only tumour necrosis factor (TNF) antagonist licensed for treatment of resistant polyarticular juvenile idiopathic arthritis (JIA) and Adalimumab recently became the second one
15th Paediatric Rheumatology European Society (PreS) Congress Wietse Kuis, Patricia Woo, Angelo Ravelli, Hermann Girschick, Michaël Hofer, Johannes Roth, Rotraud K Saurenmann, Alberto Martini, Pavla Dolezova, Janjaap van der Net, Pierre Quartier, Lucy Wedderburn and Jan Scott Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here.
Etanercept has been the only TNF antagonist licensed for treatment of resistant polyarticular juvenile idiopathic arthritis (JIA) and Adalimumab recently became the second one
Summary
Address: 1Hospital for Sick Children, Toronto, Canada and 2Asklepios Klinik, Sankt Augustin, Germany * Corresponding author from 15th Paediatric Rheumatology European Society (PreS) Congress London, UK. 14–17 September 2008. Address: 1Hospital for Sick Children, Toronto, Canada and 2Asklepios Klinik, Sankt Augustin, Germany * Corresponding author from 15th Paediatric Rheumatology European Society (PreS) Congress London, UK. Published: 15 September 2008 Pediatric Rheumatology 2008, 6(Suppl 1):P41 doi:10.1186/1546-0096-6-S1-P41. 15th Paediatric Rheumatology European Society (PreS) Congress Wietse Kuis, Patricia Woo, Angelo Ravelli, Hermann Girschick, Michaël Hofer, Johannes Roth, Rotraud K Saurenmann, Alberto Martini, Pavla Dolezova, Janjaap van der Net, Pierre Quartier, Lucy Wedderburn and Jan Scott Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
